Use of statins for arrhythmia in patients with coronary heart disease and diabetes mellitus

Shugushev Kh.Kh.; Khasanova Z.B.; Attaeva M.Zh.

doi:https://doi.org/

Shugushev Kh.Kh.

FGBOU VPO "Kabardino-Balkarskiĭ gosudarstvennyĭ universitet im. Kh.M. Berbekova" Ministerstva obrazovaniia i nauki Rossii, Nal'chik

Khasanova Z.B.

FGBOU VPO "Kabardino-Balkarskiĭ gosudarstvennyĭ universitet im. Kh.M. Berbekova" Ministerstva obrazovaniia i nauki Rossii, Nal'chik

Attaeva M.Zh.

FGBOU VPO "Kabardino-Balkarskiĭ gosudarstvennyĭ universitet im. Kh.M. Berbekova" Ministerstva obrazovaniia i nauki Rossii, Nal'chik

Use of statins for arrhythmia in patients with coronary heart disease and diabetes mellitus

Authors:

Shugushev Kh.Kh., Khasanova Z.B., Attaeva M.Zh.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2013;6(3): 33‑36

Read: 8085 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Shugushev KhKh, Khasanova ZB, Attaeva MZh. Use of statins for arrhythmia in patients with coronary heart disease and diabetes mellitus. Russian Journal of Cardiology and Cardiovascular Surgery. 2013;6(3):33‑36. (In Russ.)

Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)

Использование инфографики авторами научных работ

References:

Ametov A.S., Lysenko M.A. Sakharnyi diabet 2-go tipa i serdechno-sosudistye zabolevaniya: stolknovenie dvukh global'nykh neinfektsionnykh epidemii. Rus med zhurn 2011; 13: 802-804.
Amosova E.N. Statiny - ot effektivnosti k bezopasnosti: fokus na rozuvastatin. Sertse і sudini 2008; 1: 94-104.
Aronov D.M. Pleiotropnye effekty statinov. Rus med zhurn 2001; 9: 18-28.
Arutyunov G.P. Statiny i ostryi koronarnyi sindrom. My na poroge novogo standarta lecheniya. Serdtse 2002; 1: 44-46.
Belovol A.N., Rozhlapa L.O., Plieva I.Yu. i dr. Effektivnost' statinov pri ishemicheskoi bolezni serdtsa i sakharnom diabete. Diabet i serdtse 2011;2: 148.
Dedov I.I., Shestakova M.V. Sakharnyi diabet i arterial'naya gipertenziya. M: MIA 2006; 320-329.
Kozlova E.S., Galaktionova E.E., Nemchuk F.A., Lopatin Yu.M. Dinamika pokazatelei variabel'nosti ritma serdtsa u patsientov s paroksizmal'noi formoi fibrillyatsii predserdii pri lechenii atorvastatinom. Ratsion farmakoter v kardiol 2008; 3: 33-38.
Kozlova E.S., Nemchuk F.A., Lopatin Yu.M. Atorvastatin i narusheniya ritma serdtsa. Vzglyad na mekhanizm deistviya. Vestn Volgogradskogo GMU 2010; 33: 86-90.
Kozyrev O.A., Murashkina O.O. Antiaritmicheskie svoistva statinov - pryamoe deistvie ili oposredovannyi effekt? Vestn aritmol 2007; 49: 42-46.
Konstantinov V.O. Evolyutsiya statinovoi terapii: prodolzhenie sleduet. Serdtse 2005; 4: 199-204.
Morozova T.E., Vartanova O.A. Vtorichnaya medikamentoznaya profilaktika serdechno-sosudistykh oslozhnenii u bol'nykh ishemicheskoi bolezn'yu serdtsa i sakharnym diabetom: mesto statinov. Lech vrach 2010; 3: 18-22.
Baigent C., Keech A., Kearney P.M. et al. Efficacy and safety of cholesterol lowering treatment: rospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
Bartnik M., Rydén L., Ferrari R. et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25: 21: 1880-1890.
Briel M., Schwartz G., Thompson P. et al. Effects of Early Treatment With Statins on Short-term Clinical Outcomes in Acute Coronary Syndromes. JAMA 2006; 295: 2046-2056.
Chiu J.H., Abdelhadi R.H., Chung M.K. et al. Effect of statin therapy onrisk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol 2005; 95: 4: 490-491.
Colhoun H.M., Betteridge D.J., Durrington P.N. et al. The CARDS Investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
De Sutter J., Tavernier R., De Buyzere M. et al. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 2000; 36 :766-772.
Fauchier L., Pierre B., de Labriolle A. et al. Antiarrythmic effect of statin therapy and atrial fibrillation a metaanalysis of randomized controlled trials. J Am. Coll Cardiol 2008; 51: 828-835.
Folkeringa R.J., Van Kraaij D.J., Tieleman R.G. et al. Statins associated with reduced mortality in patients admitted for congestive heart failure. J Card Fail 2006; 12: 2: 134-138.
Hanna I.R., Dudley S.C. Jr, King-Hageman D. et al. Lipid-lowering,therapy reduces the prevalence of atrial fibrillation (Abstract). 2005 Heart Rhythm Society Scientific Sessions. New Orleans LA 2005.
Jones P.H., Davidson M.H., Stein E.A. et al. for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152-160.
Khusk K.K., Waters D.D., Bittner V. et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) Study. Circulations 2007; 115: 5: 576-583.
Kinlay S., Schwartz G.G., Olsson E. et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in Myocardial Ischemia Reduction and Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 2004; 110: 386-391.
Kumagai K., Nakashima H., Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62: 1: 105-111.
Liacopoulos O.J., Choi J.H., Haldenwang P.L. et al. Impact of preoperative statin therapy on adverge postoperative outcomes in Patients undergoing cardiac surgery: a metaanalysis of over 30 000 patients. Eur Heart J 2008; 29: 1548-1559.
Nissen S., Nicholls S.J., Sipahi I. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006; 295: 13: 1556-1565.
Nissen S.E., Nicholls S.J., Sipahi I. et al. Vliyanie vysokointensivnoi terapii statinami na regressiyu koronarnogo ateroskleroza. Terapiya 2006; 4: 3-6.
Pliquett R.U., Cornish K.G., Zucker I.H. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 2003; 95: 2: 700-704.
Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
Schuster H., Barter P.J., Stender S. et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004; 147: 705-712.
Thompson G.R. Management of dyslipidaemia. Heart Br Cardiac Soc 2004; 90: 8: 949-955.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
The ADVANCE Collaborative Group: Rationale and design of the ADVANCE Study: a randomised trial of blood pressure lowering and intensive glucose control in high risk individuals with Type 2 diabetes mellitus. J Hypertension 2001; 19: 21-28.
United Kingdom Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713.
Young-Xu Y., Jabbour S., Goldberg R. et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92: 1379-1383.